GlassScriptPhysician profile
Aditya N Dubey
NPI 1922203116
$21,148.74
in general payments reported to CMS, 2019-2025
48 companies · $4,724 in 2025
The $4,724 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $1,097 · 2021: $1,394 · 2022: $1,825 · 2023: $2,306 · 2024: $8,755 · 2025: $4,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,838 · Consulting Fee: $4,810 · Travel and Lodging: $985 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,837.54 |
| Consulting Fee | $4,810.00 |
| Travel and Lodging | $985.27 |
| Education | $152.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $6,788.32 | 2022-2025 | Tyvaso, Remodulin, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $3,526.97 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,160.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $825.08 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $786.13 | 2020-2025 | Dupixent |
| Grifols USA, LLC | $611.13 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $580.87 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.12 | 2019-2024 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $538.03 | 2020-2025 | Glassia |
| Genzyme Corporation | $483.12 | 2019-2025 | |
| Harmony Biosciences LLC | $474.46 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $434.11 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $387.63 | 2019-2025 | Xywav |
| Noah Medical Corporation | $387.16 | 2024-2025 | Galaxy |
| Electromed, INC. | $257.71 | 2019-2025 | Smartvest |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $246.71 | 2020-2025 | Arikayce |
| Pulmonx Corporation | $187.92 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $182.60 | 2023-2024 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $173.36 | 2024-2025 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2022 | |
| Zoll Respicardia, INC. | $116.83 | 2023-2025 | Remede System |
| Viatris Specialty LLC | $112.63 | 2025 | Yupelri |
| 3b Medical, INC. | $109.07 | 2025 | Luna |
| Axsome Therapeutics, INC. | $97.75 | 2023-2025 | Sunosi |
| Novo Nordisk INC | $97.48 | 2025 | Wegovy |
| Verona Pharma, INC. | $83.24 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Resmed Corp | $78.46 | 2024-2025 | |
| Vifor Pharma, INC. | $73.45 | 2024-2025 | Zemaira |
| Philips North America LLC | $66.80 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $66.22 | 2020-2022 | |
| Genentech USA, INC. | $60.06 | 2019-2024 | Xolair |
| Baxter Healthcare | $52.54 | 2024-2025 | Hillrom - Monarch Airway Clearance System |
| Nabriva Therapeutics, Plc | $43.04 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $42.55 | 2021-2023 | |
| Lilly USA, LLC | $36.09 | 2025 | Zepbound |
| Circassia INC. | $33.16 | 2021-2025 | Niox |
| Phadia US INC. | $26.32 | 2024 | Immunocap |
| Itamar Medical INC | $26.10 | 2025 | Watchpatone |
| Melinta Therapeutics, LLC | $24.72 | 2021 | |
| Vapotherm INC | $23.18 | 2021 | |
| Boston Scientific Corporation | $21.77 | 2019 | |
| Bard Peripheral Vascular, INC. | $20.67 | 2025 | Venclose Maven Catheter |
| Sunovion Pharmaceuticals INC. | $18.36 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $15.67 | 2024 | Opsumit |
| Vanda Pharmaceuticals INC. | $14.25 | 2021 | |
| Pfizer INC. | $13.30 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Dubey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.